We used the small molecule ISRIB (Integrated Stress Response Inhibitor), an activator of eIF2B [38], to examine the potential role of eIF2α signaling in the response to bortezomib and VLX1570 in ALL cells. This evidence concerns the gene EIF2A and acute lymphoblastic leukemia.